TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

In the overall study population, TX45 achieved a 17.9% reduction in pulmonary capillary wedge pressure (“PCWP”), an endpoint known to correlate with exercise capacity, morbidity and mortality ...

One study indicated that EIPH-positive horses had higher hematocrit values, which may contribute to increased pulmonary capillary pressure, a factor in the development of EIPH[1]. Additionally ...

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Artery Vein Capillary Function Carry blood away from the heart (usually oxygenated blood, except for the pulmonary artery ... withstand blood flowing at high pressure as it leaves the heart ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...